These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23948442)

  • 1. Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts.
    Evans ND; Dimelow RJ; Yates JW
    Comput Methods Programs Biomed; 2014 May; 114(3):e3-13. PubMed ID: 23948442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR
    Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models.
    Yoo GH; Subramanian G; Piechocki MP; Ensley JF; Kucuk O; Tulunay OE; Lonardo F; Kim H; Won J; Stevens T; Lin HS
    Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):735-42. PubMed ID: 18645124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
    Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models.
    Izbicka E; Campos D; Marty J; Carrizales G; Mangold G; Tolcher A
    Anticancer Res; 2006; 26(3A):1983-8. PubMed ID: 16827133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
    Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel fluorinated docetaxel analogues.
    Lu HF; Sun X; Xu L; Lou LG; Lin GQ
    Eur J Med Chem; 2009 Feb; 44(2):482-91. PubMed ID: 18524425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy.
    Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF
    Br J Cancer; 2015 Mar; 112(5):832-40. PubMed ID: 25647012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
    Adema AD; Laan AC; Myhren F; Fichtner I; Verheul HM; Sandvold ML; Peters GJ
    Int J Oncol; 2010 Jan; 36(1):285-94. PubMed ID: 19956857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An experimental model comparing the antineoplastic and the immunosuppressive effects of some cytostatics.
    Ghyka G; Haraga L
    Arch Roum Pathol Exp Microbiol; 1989; 48(1):33-45. PubMed ID: 2802968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
    Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
    Naito M; Matsuba Y; Sato S; Hirata H; Tsuruo T
    Clin Cancer Res; 2002 Feb; 8(2):582-8. PubMed ID: 11839680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.